Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Change in Accured Expenses of $20.8 million for Q1 2026, up 9804.67% year-over-year from $209678.8 in Q1 2025, and down 11.44% quarter-over-quarter from $23.5 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $20.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 9804.67% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $71.0 million (up 120.91% YoY), while the FY2025 annual figure was $50.0 million, up 56.23% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $20.8 million, down from $23.5 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $23.5 million in Q4 2025, with the low at -$5.5 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is $5.9 million (2023), against an average of $6.4 million.
- The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses sank 234.77% in 2023, then surged 9804.67% in 2026.
- Arcutis Biotherapeutics' Change in Accured Expenses stood at $616000.0 in 2022, then soared by 860.55% to $5.9 million in 2023, then jumped by 122.8% to $13.2 million in 2024, then surged by 77.9% to $23.5 million in 2025, then dropped by 11.44% to $20.8 million in 2026.
- Business Quant data shows ARQT's Change in Accured Expenses at $20.8 million in Q1 2026, $23.5 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 9.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.96 Mn |
| Jun 30, 2026 | 9.96 Mn |
| Mar 31, 2026 | 20.77 Mn |
| Mar 31, 2026 | 20.77 Mn |
| Dec 31, 2025 | 23.45 Mn |
| Dec 31, 2025 | 23.45 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 21.23 Mn |
| Jun 30, 2025 | 21.23 Mn |
| Mar 31, 2025 | -214,000.00 |
| Mar 31, 2025 | -214,000.00 |
| Dec 31, 2024 | 13.18 Mn |
| Dec 31, 2024 | 13.18 Mn |
| Sep 30, 2024 | 10.12 Mn |
| Sep 30, 2024 | 10.12 Mn |
| Jun 30, 2024 | 9.06 Mn |
| Jun 30, 2024 | 9.06 Mn |
| Mar 31, 2024 | -332,000.00 |
| Mar 31, 2024 | -332,000.00 |